– Near term payment to Esperion of $100 million plus $25 million in calendar quarter following EMA’s expected decision on Type II(a) variation approval of NILEMDO® (bempedoic acid) Tablet and ...
Daiichi Sankyo Europe is pleased to announce the development of a fixed-triple oral combination lipid-lowering tablet of bempedoic acid, ezetimibe, and different doses of a statin, with the potential ...
Esperion ESPR announced that it has signed an amendment to its existing collaboration with Daiichi Sankyo Europe (DSE), which is valued at $125 million. One of the terms of this agreement also ...
"By combining precise tumour targeting with an immunotherapy payload, Daiichi Sankyo is exploring a new way to harness the ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Ann Arbor-based drug maker Esperion Therapeutics Inc. and ...
Daiichi Sankyo’s DS3610 enters clinical development in patients with advanced solid tumours: Tokyo Wednesday, November 12, 2025, 11:00 Hrs [IST] Daiichi Sankyo, an innovative gl ...
[Foreign Language] Thank you for waiting. We would like to open Fiscal Year 2023 Financial Results Presentation. I'm Asakura of Corporate Communication. I will serve as MC. Concerning the language, in ...
ANN ARBOR, Mich. & MUNICH--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE) the European headquarter organization of the Japanese pharmaceutical company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback